Navigation Links
Cardica Announces $10 Million At-The-Market Common Stock Financing Agreement
Date:12/16/2010

plans to launch the Cardica Microcutter ES8, subject to FDA clearance, in the appropriate manner, while continuing development of other devices within our planned microcutter product line," said Bernard A. Hausen, M.D., Ph.D., president and chief executive officer of Cardica.

The securities issuable under the common stock purchase agreement with Aspire Capital have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration under the Securities Act of 1933 and applicable state securities laws or available exemptions from registration requirements.  Cardica has filed a registration statement for the sale by Aspire Capital of the shares of common stock issuable under the common stock purchase agreement.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About Cardica

Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and endoscopic surgical procedures. Cardica's technology portfolio is intended to minimize operating time and enable minimally-invasive and robot-assisted surgeries. Cardica manufactures and markets its automated anastomosis systems, the C-Port®  Distal Anastomosis Systems and PAS-Port®  Proximal Anastomosis System, for coronary artery bypass graft (CABG) surgery and has shipped over 31,000 units throughout the world. In addition, the company is developing the Cardica Microcutter ES8, a true multi-fire endoscopic stapling device designed to be used in a variety of procedures, including bariatric, thoracic and general surgery. The Cardica Microcutter ES8 requires regulatory clearance through the 510(k) or other process with the U.S
'/>"/>

SOURCE Cardica, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cardica Announces Fiscal 2011 First Quarter Financial Results
2. Cardicas Automated Anastomosis Systems Featured at Advances In Robotic And Hybrid Coronary Revascularization Meeting
3. Cardica Announces Fiscal 2010 Fourth Quarter and Year End Financial Results
4. Cardica and Intuitive Surgical Enter Into License Agreement
5. Cardica to Announce Fiscal 2010 Fourth Quarter and Year End Financial Results on Tuesday, August 17, 2010
6. Cardica to Present at 9th Annual Needham Healthcare Conference on Wednesday, June 9, 2010
7. Cardica to Announce Fiscal 2010 Third Quarter Financial Results on Tuesday, May 4, 2010
8. Cardica Announces Fiscal 2010 Second Quarter Financial Results
9. Cardica Announces Fiscal 2010 First Quarter Financial Results and Business Progress
10. Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
11. Cardica to Host Investor Briefing on Revolutionizing Revascularization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
(Date:8/19/2014)... Md. , Aug. 19, 2014  Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... offering announced last Thursday, August 14, 2014, has closed.  ... are convertible at $7.30 per share of common stock.  ... months, to purchase up to an additional 30% of ...
(Date:8/19/2014)... YORK , Aug. 19, 2014  As ... around the country, Bernstein Liebhard LLP notes that ... can choose between a number of options that ... dangerous surgical instrument. According to a report published ... th , these options include a mini-laparotomy and ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3
... 24 Children,s Mental Focus,Foundation (CMFF), a nonprofit ... that may be linked to children with autism ... currently working with,doctors that have patients afflicted with ... adults cope with behavioral problems,associated with mental disorders ...
... Marketers, who have the,primary responsibility for communicating the ... as top challenges for pharmaceutical,companies when communicating trial ... worry about competitors stealing your,thunder, but also worry ... According to a Best Practices, LLC benchmarking study, ...
Cached Medicine Technology:Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 2Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 3Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies 2
(Date:8/20/2014)... (PRWEB) August 20, 2014 Doctors at the ... to wipe out mesothelioma in laboratory mice by injecting them ... just posted details of the study on its website. ... Scientists with Hong Kong University’s AIDS Institute of Microbiology created ... 1” or PD-1. By altering DNA, the vaccine is designed ...
(Date:8/20/2014)... City, New Jersey (PRWEB) August 20, 2014 ... in meeting the needs of an estimated tens of ... introduction of the new Bill A3525—a bill that would ... patients to grow their own cannabis—earlier this summer by ... horticultural training for medicinal quality marijuana is growing. , ...
(Date:8/20/2014)... August is Children’s Eye Health and Safety ... eye health and safety for their children and have ... that must be checked for, according to Sharon Kleyne, ... radio show, is pediatric dry eye. With computer use ... is becoming a very real concern to ophthalmologists. , ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Hope For ... Give Hope® Celebration to be hosted in Washington, DC ... Navy Club. This signature event honors the courage of ... of the fallen. Proceeds from the Got Heart, Give ... national nonprofit dedicated to restoring a sense of self, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Building ... healthcare, Jvion successfully predicted stage iii and iv ... in some situations, approached 90%. A company spokesperson ... achieved in commercial or academic settings. The resulting ... all types of hospital-acquired conditions to help providers ...
Breaking Medicine News(10 mins):Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2
... The findings might boost understanding of the disease generally, ... The adult children of people with the rarer, inherited ... new study to better understand the biology of the ... biological parent diagnosed with a known genetic mutation causing ...
... 28 /PRNewswire-Asia/ -- CCID Consulting, China,s leading,research, consulting and ... listed in Hong Kong (Hong Kong Stock Exchange:,HK08235), recently ... , In 2007, ... an increase,in health awareness, which in turn drove the ...
... MD, noted medical researcher and women,s health practitioner, has spoken out ... well as other oral bisphosphonates such as Boniva, Actonel, and Fosamax. ... ... Susan Lark, MD , noted medical researcher and women,s health ...
... Africa, Nov. 27 20 top international,and local companies ... Awards Banquet held tonight at the Michelangelo Hotel in ... and innovation,across a variety of sectors. , ... , The awards ...
... after its use was banned, statistics show that nearly 4,000 people in the ... , ... Manchester,UK (PRWEB) November 27, 2008 -- On 24th November 1999, the Government,s ... statistics show that nearly 4,000 people in the UK die each year from ...
... care nurses are considering quitting in the next year ... Melbourne study. , The study, conducted by the Centre ... and the Australian Nursing Federation finds Victoria,s registered nurses ... not committed to their workplace. , It cites excessive ...
Cached Medicine News:Health News:Study Recruiting From Alzheimer's-Prone Families 2Health News:CCID Consulting Discusses China's Medical Equipment Market 2Health News:CCID Consulting Discusses China's Medical Equipment Market 3Health News:CCID Consulting Discusses China's Medical Equipment Market 4Health News:CCID Consulting Discusses China's Medical Equipment Market 5Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 2Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 3Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 4Health News:Frost & Sullivan Recognises Best-in-Class Innovators 2Health News:Frost & Sullivan Recognises Best-in-Class Innovators 3Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 2Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 3Health News:Aged care workers to leave industry en masse due to stress, warns University of Melbourne study 2
Inquire...
Inquire...
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... Fractionation, Proteins and Viruses • ... with fixed-angle rotor • Spin ... 85 mL • Operating temperature ... C • Rotors certified by ...
Medicine Products: